ARTICLE | Clinical News
JX-594: Phase I/IIa started
March 26, 2012 7:00 AM UTC
Molecular target: Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2)
Description: Recombinant vaccinia virus (addition of granulocyte macrophage colony-stimulating factor (GM-CSF) and deletion of thymidine kinase)...